Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Publication | Closed Access

DOI

1.4K

Citations

References

2019

Year

Claus Bachert, Joseph K. Han, Martin Desrosiers, Peter W. Hellings, Nikhil Amin, Stella E. Lee, Joaquim Mullol, Leon S. Greos, John V. Bosso, Tanya M. Laidlaw,

The Lancet

AsthmaNasal PolypsAllergyLiberty Np Sinus-52Endoscopic Sinus SurgeryAllergic RhinitisMedicineAllergic RhinoconjunctivitisSinusitisSevere Chronic Rhinosinusitis